| 2025-05-05 | -0.3 % |
|
| 2025-05-02 | +0.87 % |
|
| 2025-05-01 | -2.12 % |
|
| 2025-04-30 | +0.34 % |
|
| 2025-04-29 | +1.47 % |
|
| 2025-04-28 | -0.68 % |
|
| 2025-04-25 | -0.57 % |
|
| 2025-04-24 | -1.15 % |
|
| 2025-04-23 | -0.71 % |
|
| 2025-04-22 | +3.05 % |
|
| 2025-04-21 | -1.32 % |
|
| 2025-04-17 | -2.13 % |
|
| 2025-04-16 | -0.95 % |
|
| 2025-04-15 | -1.85 % |
|
| 2025-04-10 | -5.76 % |
|
| 2025-04-09 | +8.17 % |
|
| 2025-04-07 | -0.01 % |
|
| 2025-04-04 | -6.83 % |
|
| 2025-04-03 | -3.89 % |
|
| 2025-04-02 | +1.26 % |
|
| 2025-04-01 | -2.94 % |
|
| 2025-03-31 | -0.51 % |
|
| 2025-03-27 | -0.39 % |
|
| 2025-03-25 | -1.07 % |
|
| 2025-03-24 | +0.42 % |
|
| 2025-03-21 | -0.18 % |
|
| 2025-03-19 | -0.59 % |
|
| 2025-03-18 | +0.37 % |
|
| 2025-03-14 | +2.58 % |
|
| 2025-03-13 | -0.73 % |
|
| 2025-03-12 | -0.3 % |
|
| 2025-03-11 | -2.39 % |
|
| 2025-03-07 | +0.77 % |
|
| 2025-03-06 | +0.66 % |
|
| 2025-02-27 | -1.89 % |
|
| 2025-02-19 | +1.49 % |
|
| 2025-02-18 | -1.65 % |
|
| 2025-02-13 | -1 % |
|
| 2025-02-07 | -0.22 % |
|
| 2025-02-05 | +0.31 % |
- Thermo Fisher Scientific's stock (TMO) experienced a 0.31% increase, likely due to strong investor interest in biotech stocks following recent high trading volumes among key players in the industry, signifying market confidence in their growth potential.
- Thermo Fisher Scientific (TMO) stock rose by 0.31% last night, driven by a combination of positive analyst upgrades, strong earnings performance that surpassed expectations, and a significant stock repurchase plan indicating management's belief in the stock's undervaluation.
- Thermo Fisher Scientific's stock (TMO) rose by 0.31% following the reaffirmation of an "outperform" rating by Raymond James, which increased its price target from $650.00 to $667.00, signaling expected growth and positive sentiment among analysts regarding the company's performance.
- Thermo Fisher Scientific's stock (TMO) rose by 0.31% following an increase in target prices by several analysts, including Scotiabank, which raised its target from $605 to $650, suggesting a potential upside for investors.
|
| 2025-02-03 | -0.67 % |
- Thermo Fisher Scientific (TMO) stock experienced a decline of -0.67% despite an increase in its price target by UBS Group from $700 to $715, primarily due to mixed analyst ratings and insider selling, which may have raised concerns among investors about the company's stock value.
- Thermo Fisher Scientific (TMO) stock fell by 0.67% due to mixed analyst ratings, with a recent downgrade from Bank of America and concerns regarding stock performance, despite being rated as a "Moderate Buy" by most analysts.
- The article discusses Banzai International, Inc.'s acquisition of Vidello, a video hosting and marketing suite provider, aimed at enhancing Banzai's revenue growth and AI-powered marketing solutions.
The drop in Thermo Fisher Scientific (TMO) stock by 0.67% could not be directly attributed to the article, but it may relate to broader market factors or company-specific news affecting investor sentiment.
- Thermo Fisher Scientific (TMO) stock fell by 0.67% following a downgrade in Q1 2025 earnings per share projections by Leerink Partners, which revised its estimate from $5.43 to $5.10, contributing to market concerns about the company's financial outlook.
|
| 2025-01-30 | +6.78 % |
|
| 2025-01-27 | +1.53 % |
|
| 2025-01-23 | +0.05 % |
|
| 2025-01-22 | +0.27 % |
- Thermo Fisher Scientific's stock (TMO) rose by 0.27%, likely due to favorable earnings performance, a share buyback program indicating management's belief in the stock's undervaluation, and continuing support from institutional investors, despite some recent insider selling.
- Thermo Fisher Scientific (TMO) stock rose by 0.27% last night as it remains one of the biotech stocks to watch, showing strong trading volume amid overall investor interest in the biotech sector.
The increase in TMO stock may be attributed to heightened investor confidence in the biotechnology sector, which includes a focus on life sciences and healthcare innovations, thus driving demand for shares.
- Thermo Fisher Scientific (TMO) stock increased by 0.27% following reports of growing institutional investments, including a 4.1% increase in holdings by Wedge Capital Management, and a successful earnings report that exceeded expectations, alongside the announcement of a $4 billion stock repurchase program, indicating confidence in the company's undervalued stock.
|
| 2025-01-21 | +2.4 % |
|
| 2025-01-17 | -0.37 % |
|
| 2025-01-16 | +1.86 % |
|
| 2025-01-15 | -0.99 % |
|
| 2025-01-14 | +0.26 % |
|
| 2025-01-13 | +2.44 % |
|
| 2025-01-10 | -0.48 % |
|
| 2025-01-08 | -0.13 % |
|
| 2025-01-06 | +0.97 % |
|
| 2025-01-03 | +1.81 % |
|
| 2025-01-02 | +0.45 % |
|
| 2024-12-20 | +1.42 % |
|
| 2024-12-19 | +0.1 % |
|
| 2024-12-17 | -0.27 % |
|
| 2024-12-10 | -0.26 % |
|
| 2024-12-04 | -1.04 % |
|
| 2024-12-03 | +0.84 % |
|
| 2024-11-27 | +1.69 % |
|
| 2024-11-26 | -0.24 % |
|
| 2024-11-25 | +0.18 % |
|
| 2024-11-18 | -2.3 % |
|
| 2024-11-12 | -1.13 % |
|
| 2024-11-08 | -0.75 % |
|
